| Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study G Meyer, Z Marjanovic, J Valcke, B Lorcerie, Y Gruel, P Solal-Celigny, ... Archives of internal medicine 162 (15), 1729-1735, 2002 | 1055 | 2002 |
| BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines JM Hoang, PH Cottu, B Thuille, RJ Salmon, G Thomas, R Hamelin Cancer research 57 (2), 300-303, 1997 | 557 | 1997 |
| Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ... The lancet oncology 14 (10), 933-942, 2013 | 505 | 2013 |
| miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response B Mateescu, L Batista, M Cardon, T Gruosso, Y De Feraudy, O Mariani, ... Nature medicine 17 (12), 1627-1635, 2011 | 502 | 2011 |
| A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) H Bonnefoi, T Grellety, O Tredan, M Saghatchian, F Dalenc, A Mailliez, ... Annals of Oncology 27 (5), 812-818, 2016 | 286 | 2016 |
| Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis FC Bidard, S Michiels, S Riethdorf, V Mueller, LJ Esserman, A Lucci, ... JNCI: Journal of the National Cancer Institute 110 (6), 560-567, 2018 | 261 | 2018 |
| Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer F Riva, FC Bidard, A Houy, A Saliou, J Madic, A Rampanou, C Hego, ... Clinical chemistry 63 (3), 691-699, 2017 | 235 | 2017 |
| Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study J Glasbey, A Ademuyiwa, A Adisa, E AlAmeer, AP Arnaud, F Ayasra, ... The Lancet Oncology 22 (11), 1507-1517, 2021 | 230 | 2021 |
| Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines J Gayet, XP Zhou, A Duval, S Rolland, JM Hoang, P Cottu, R Hamelin Oncogene 20 (36), 5025-5032, 2001 | 226 | 2001 |
| Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients—preliminary evidence of activity S Delaloge, A Yovine, A Taamma, M Riofrio, E Brain, E Raymond, P Cottu, ... Journal of Clinical Oncology 19 (5), 1248-1255, 2001 | 219 | 2001 |
| Molecular profiling of patient-derived breast cancer xenografts F Reyal, C Guyader, C Decraene, C Lucchesi, N Auger, F Assayag, ... Breast cancer research 14, 1-14, 2012 | 215 | 2012 |
| Survival of breast cancer patients with meningeal carcinomatosis H Gauthier, MN Guilhaume, FC Bidard, JY Pierga, V Girre, PH Cottu, ... Annals of oncology 21 (11), 2183-2187, 2010 | 188 | 2010 |
| Allelic profiles of mononucleotide repeat microsatellites in control individuals and in colorectal tumors with and without replication errors XP Zhou, JM Hoang, P Cottu, G Thomas, R Hamelin Oncogene 15 (14), 1713-1718, 1997 | 158 | 1997 |
| Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis AR Ferreira, A Di Meglio, B Pistilli, AS Gbenou, M El-Mouhebb, S Dauchy, ... Annals of Oncology 30 (11), 1784-1795, 2019 | 157 | 2019 |
| Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification CKY Ng, LG Martelotto, A Gauthier, HC Wen, S Piscuoglio, RS Lim, ... Genome biology 16, 1-21, 2015 | 150 | 2015 |
| Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort A Darlix, G Louvel, J Fraisse, W Jacot, E Brain, M Debled, ... British journal of cancer 121 (12), 991-1000, 2019 | 145 | 2019 |
| Distinct tumor protein p53 mutants in breast cancer subgroups A Dumay, JP Feugeas, E Wittmer, J Lehmann‐Che, P Bertheau, M Espié, ... International journal of cancer 132 (5), 1227-1231, 2013 | 142 | 2013 |
| Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. PH Cottu, F Muzeau, A Estreicher, JF Fléjou, R Iggo, G Thomas, ... Oncogene 13 (12), 2727-2730, 1996 | 140 | 1996 |
| Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience L Staudacher, PH Cottu, V Dieras, A Vincent-Salomon, MN Guilhaume, ... Annals of oncology 22 (4), 848-856, 2011 | 139 | 2011 |
| COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area P Vuagnat, M Frelaut, T Ramtohul, C Basse, S Diakite, A Noret, ... Breast Cancer Research 22, 1-10, 2020 | 138 | 2020 |
